Regulatory T Cells
Phase 1Biologic
Regulatory T Cells is one of 88 biologic programs targeting Liver Transplant. It is currently in Phase 1.
3
Indications
6
Total Trials
0
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Stelara
Johnson & JohnsonPhase 3
Tremfya
Johnson & JohnsonPhase 3
Purinethol
SStason
Phase 3
SHR0302
RReistone Biopharma Company Limited
Phase 3
SPD476
TakedaPhase 3
Simponi
Johnson & JohnsonPreclinical
Remicade
OOrganon and Co
Preclinical
Humira
CCelltrion
Preclinical
HMPL-004
HHutchison Medipharma Limited
Phase 3
Budesonide-MMX
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic GVHD1 trial
Liver Transplant1 trial
Infusion1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Regulatory T Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanjing Medical University